Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.55 |
| ▸ | ITGAV | P06756 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 3/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641195 | 1.00 | FOLH1 (0.60) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL19658555 | 1.00 | FOLH1 (0.60) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL6841663 | 0.96 | FOLH1 (0.58) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL7515531 | 0.96 | FOLH1 (0.58) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL8387978 | 0.94 | FOLH1 (0.65) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL18366279 | 0.92 | HDAC1 (0.55) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL19659180 | 0.92 | HDAC1 (0.55) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL10421088 | 0.91 | FOLH1 (0.62) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL1111208 | 0.90 | PPARA (0.55) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL1111209 | 0.90 | PPARA (0.55) | FOLH1SIRT2SIRT1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-112979660-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| CN-111269221-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-8735135-B2 | Transformed strains originated from multidrug efflux protein defective strains and a method for microbial conversion using them | MICROBIOPHARM JAPAN CO., LTD (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2130907-B1 | TRANSFORMED STRAIN DERIVED FROM STRAIN DEFICIENT IN MULTIDRUG EFFLUX PROTEIN, AND BIOCONVERSION METHOD USING THE SAME | MICROBIOPHARM JAPAN CO LTD (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20120040441-A1 | TRANSFORMED STRAINS ORIGINATED FROM MULTIDRUG EFFLUX PROTEIN DEFECTIVE STRAINS AND A METHOD FOR MICROBIAL CONVERSION USING THEM | MERCIAN CORPORATION (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2130907-A1 | TRANSFORMED STRAIN DERIVED FROM STRAIN DEFICIENT IN MULTIDRUG EFFLUX PROTEIN, AND BIOCONVERSION METHOD USING THE SAME | MERCIAN CORPORATION (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20040249205-A1 | Process for producing hydroxyamino acid derivative | MERCIAN CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| WO-2004072047-A1 | INDOLES, BENZIMIDAZOLES OR NAPHHIMIDAZOLES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-26 | — | — | WO | disclosed |
| CN-1106001-A | Lactol derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249205-A1 | Process for producing hydroxyamino acid derivative | HAAO, HDGF, BCAT1 | FOLH1 666/4885SIRT2 2496/4885SIRT1 3633/4885 |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | FOLH1 1770/4885SIRT2 1787/4885SIRT1 794/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | FOLH1 4661/4885SIRT2 2284/4885SIRT1 1283/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | FOLH1 1770/4885SIRT2 1787/4885SIRT1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.